UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 321

Sortiert nach

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Annals of oncology, 2017-05, Vol.28 (5), p.996-1004

2017

Volltextzugriff (PDF)

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

Annals of oncology, 2017-03, Vol.28 (3), p.505-511

2017

Volltextzugriff (PDF)

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus

Gynecologic oncology, 2007-11, Vol.107 (2), p.177-185

2007

Volltextzugriff (PDF)

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

Gynecologic oncology, 2022-07, Vol.166 (1), p.44-49

2022

Volltextzugriff (PDF)

Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?

Gynecologic oncology, 2012-04, Vol.125 (1), p.94-98

2012

Volltextzugriff (PDF)

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

Gynecologic oncology, 2013-04, Vol.129 (1), p.86-91

2013

Volltextzugriff (PDF)

Prevalence of Lynch Syndrome-Associated Tumors in Minority Patients with Endometrial Cancer

Gynecologic oncology, 2016-10, Vol.143 (1), p.212-212

2016

Volltextzugriff (PDF)

Interdisciplinary Clinical Lactation Training at an Academic Medical Center

Journal of the Academy of Nutrition and Dietetics, 2018-10, Vol.118 (10), p.A141-A141

2018

Volltextzugriff (PDF)

Updated 4-Year Results for NRG Oncology / RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S49-S50

2016

Volltextzugriff (PDF)

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

Gynecologic oncology, 2012-06, Vol.125 (3), p.771-771

2012

Volltextzugriff (PDF)

Analysis of survivorship in high-risk patients on treated on GOG-218

Gynecologic oncology, 2013-07, Vol.130 (1), p.e112-e113

2013

Volltextzugriff (PDF)

Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab

Gynecologic oncology, 2013-07, Vol.130 (1), p.e33-e34

2013

Volltextzugriff (PDF)

Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab

Gynecologic oncology, 2013-07, Vol.130 (1), p.e120-e120

2013

Volltextzugriff (PDF)

Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity

Gynecologic oncology, 2012-03, Vol.125, p.S22-S22

2012

Volltextzugriff (PDF)

Assessment of patients with endometrioid adenocarcinoma (EC) of the uterus falling in the ‘gap’ between PORTEC 1 high intermediate risk and GOG 99 high intermediate risk (HIR)

Gynecologic oncology, 2012-03, Vol.125, p.S160-S160

2012

Volltextzugriff (PDF)

Outcomes in patients with surgically staged, high-intermediate risk endometrial cancer in the absence of adjuvant therapy

Gynecologic oncology, 2011-03, Vol.120, p.S33-S34

2011

Volltextzugriff (PDF)

Late toxicity of chemoradiotherapy: An underrecognized source of morbidity in survivors of locally advanced carinoma of the uterine cervix

Gynecologic oncology, 2011-03, Vol.120, p.S109-S109

2011

Volltextzugriff (PDF)

Surgical Management of Early-Stage Endometrial Cancer in the Elderly: Is Laparoscopy Feasible?

Gynecologic oncology, 2001-12, Vol.83 (3), p.563-568

2001

Volltextzugriff (PDF)

Robotic versus open radical hysterectomy for invasive cervical cancer: A single institution review of the first 3 years of practice

Gynecologic oncology, 2011-11, Vol.123 (2), p.430-430

2011

Volltextzugriff (PDF)

Cost Analysis of Laparoscopy versus Laparotomy for Early Endometrial Cancer

Gynecologic oncology, 1999-12, Vol.75 (3), p.460-463

1999

Volltextzugriff (PDF)

Do uterine risk factors or lymph node metastases drive overall recurrence risk in patients with endometrial cancer?

Gynecologic oncology, 2011-03, Vol.120, p.S33-S33

2011

Volltextzugriff (PDF)

Positive vulvar sentinel lymph node biopsy: A single-institution retrospective review

Gynecologic oncology, 2011-03, Vol.120, p.S119-S119

2011

Volltextzugriff (PDF)

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

Journal of clinical oncology, 2021-11, Vol.39 (32), p.3623-3632

2021

Volltextzugriff (PDF)

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

Annals of oncology, 2005-10, Vol.16 (suppl-8), p.viii13-viii19

2005

Volltextzugriff (PDF)

1 – 25 von 321

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(294)
Mit Volltextzugriff
(289)

Publikationsform

Sprache

Englisch
(312)
Japanisch
(47)
Deutsch
(9)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?

A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study

Prevalence of Lynch Syndrome-Associated Tumors in Minority Patients with Endometrial Cancer

Interdisciplinary Clinical Lactation Training at an Academic Medical Center

Updated 4-Year Results for NRG Oncology / RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

Analysis of survivorship in high-risk patients on treated on GOG-218

Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab

Time from completion of chemotherapy to disease progression as a clinically relevant endpoint in women with epithelial ovarian, primary peritoneal, and fallopian tube cancers treated with and without bevacizumab

Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity

Assessment of patients with endometrioid adenocarcinoma (EC) of the uterus falling in the ‘gap’ between PORTEC 1 high intermediate risk and GOG 99 high intermediate risk (HIR)

Outcomes in patients with surgically staged, high-intermediate risk endometrial cancer in the absence of adjuvant therapy

Late toxicity of chemoradiotherapy: An underrecognized source of morbidity in survivors of locally advanced carinoma of the uterine cervix

Surgical Management of Early-Stage Endometrial Cancer in the Elderly: Is Laparoscopy Feasible?

Robotic versus open radical hysterectomy for invasive cervical cancer: A single institution review of the first 3 years of practice

Cost Analysis of Laparoscopy versus Laparotomy for Early Endometrial Cancer

Do uterine risk factors or lymph node metastases drive overall recurrence risk in patients with endometrial cancer?

Positive vulvar sentinel lymph node biopsy: A single-institution retrospective review

Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens

Suchergebnisse filtern